Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

The objective of this study was to evaluate radiolabeled DOTA-SP90 as a radiotracer for breast cancer. The in vitro competition assay showed that radiolabeled DOTA-SP90 had significant binding affinity to BT-483 cancer cells. Biodistribution, nanoSPECT/CT and nanoPET/CT imaging results indicated that radiolabeled DOTA-SP90 can accumulate in tumors. In addition, radiolabeled DOTA-SP90 peptides can also detect metastatic tumors. Therefore, radiolabeled SP90 peptide may provide the potential capability as diagnostic agent for breast cancer patients. Copyright © 2020 Elsevier Ltd. All rights reserved.

Citation

Wei-Lin Lo, Chen-Hsien Liang, Liang-Cheng Chen, Shih-Ying Lee, Sheng-Nan Lo, Ming-Wei Chen, Ruei-Min Lu, I-Ju Liu, Han-Chung Wu, Chih-Hsien Chang. Imaging and biodistribution of radiolabeled SP90 peptide in BT-483 tumor bearing mice. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2020 Jul;161:109162

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 32561130

View Full Text